<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927611</url>
  </required_header>
  <id_info>
    <org_study_id>CSPAC-NEN-1</org_study_id>
    <nct_id>NCT04927611</nct_id>
  </id_info>
  <brief_title>Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm</brief_title>
  <official_title>Single-cell Sequencing and Establishment of Cell Lines, Organoids, and Transplanted Tumor Models in Neuroendocrine Neoplasm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>D1 Medical Technology (Shanghai) Co., Ltd, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to use single-cell sequencing technology to explore neuroendocrine&#xD;
      neoplasm (NEN) molecular biological characteristics, tumor heterogeneity and cell subtypes.&#xD;
      Besides. NEN models are constructed for basic research, including primary cell lines,&#xD;
      organoids, and animal models.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuroendocrine neoplasm (NEN) generally refers to all tumors that originate from peptidergic&#xD;
      neurons and neuroendocrine cells. It is a relatively rare tumor, ranging from indolent,&#xD;
      slow-growing low-grade malignant tumors to obvious distant metastases. A series of malignant&#xD;
      tumors. The most common place for neuroendocrine tumors is in the digestive system, and about&#xD;
      two-thirds of neuroendocrine tumors occur in the gastrointestinal pancreas. However, with the&#xD;
      change of people's living habits and the improvement of physical examination awareness, the&#xD;
      incidence of neuroendocrine tumors increased from 1.09/100,000 in 1973 to 6.98/100,000 in&#xD;
      2012. The incidence has increased by 6 times compared with other tumors. , NENs increase more&#xD;
      rapidly. The incidence of people over 65 years of age has increased by 8 times, and the&#xD;
      incidence of people younger than 50 years of age has also increased by 3 times, and the&#xD;
      incidence has been increasing year by year. It is worth noting that the average age of&#xD;
      pancreatic neuroendocrine tumors is only 56.7-13.3 years old, showing a younger trend.&#xD;
&#xD;
      Because most neuroendocrine tumors lack specific manifestations, coupled with unique inert&#xD;
      biological characteristics, clinicians often lack understanding, which can easily lead to&#xD;
      misdiagnosis and treatment. Taking gastrointestinal pancreatic neuroendocrine tumors&#xD;
      (GEP-NEN) as an example, due to the uneven diagnosis and treatment level, GEP-NEN patients&#xD;
      may be diagnosed with a delay of up to 7 years. Because of this, as many as 40-95% of GEP-NEN&#xD;
      patients have developed distant metastases at the time of diagnosis, and 65-95% of them have&#xD;
      liver metastases. Liver metastasis is the most critical prognostic risk factor in GEP-NEN,&#xD;
      and it has a decisive impact on the survival of patients. The 5-year survival rate of&#xD;
      gastrointestinal neuroendocrine tumors with liver metastasis is 56%-83%, while the 5-year&#xD;
      survival rate of pancreatic neuroendocrine tumors is only 48.8%, and the 10-year survival&#xD;
      rate is only 30.2%. For limited-stage patients, even if radical surgical resection, up to 94%&#xD;
      of cases will still have recurrence and metastasis within 5 years. For inoperable patients,&#xD;
      although chemotherapy, targeted therapy, biological therapy and other methods can be used,&#xD;
      the effect is still limited. Therefore, the systematic development of basic-clinical&#xD;
      translational research on neuroendocrine tumors is very important and imminent.&#xD;
&#xD;
      Based on the above-mentioned problems, this project intends to conduct a systematic and&#xD;
      in-depth study of neuroendocrine tumors: 1. Use single-cell sequencing technology to deeply&#xD;
      study the molecular biological characteristics of NEN tumors, tumor heterogeneity and cell&#xD;
      subtypes. 2. Construct NEN models, including primary cell lines, organoids, and mouse animal&#xD;
      models. This study can establish a neuroendocrine tumor research system to find the molecular&#xD;
      mechanism and potential intervention targets of NEN recurrence and metastasis, and provide&#xD;
      clinicians with safe and effective treatment strategies, thereby improving the therapeutic&#xD;
      effect of neuroendocrine tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bioinformatics analysis of single-cell sequencing results</measure>
    <time_frame>Half a year</time_frame>
    <description>Analysis of NEN Molecular Biology Information Using Single Cell Sequencing Technology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Model construction</measure>
    <time_frame>One year</time_frame>
    <description>Collect fresh specimens of NEN to cultivate primary cell lines, construct organoids, and establish animal models of NEN</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploration of NEN organoid</measure>
    <time_frame>One year</time_frame>
    <description>To explore and optimize the medium scheme of NEN orgnoid and methods of histomorphological identification of type organs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor microenvironment</measure>
    <time_frame>One year</time_frame>
    <description>The tumor microenvironment of NEN was analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of mechanism of NEN with PDAC</measure>
    <time_frame>Half a year</time_frame>
    <description>Collect fresh specimens of pancreatic ductal adenocarcinoma (PDAC) for single-cell sequencing and organoid construction for comparison with NEN</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Neuroendocrine Neoplasm</condition>
  <arm_group>
    <arm_group_label>Gastroenteropancreatic neuroendocrine neoplasms</arm_group_label>
    <description>Collect biopsy/surgical fresh tissue of gastroenteropancreatic neuroendocrine neoplasms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreatic ductal adenocarcinoma</arm_group_label>
    <description>Collect biopsy/surgical fresh tissue of pancreatic ductal adenocarcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy, open or laparoscopic surgery</intervention_name>
    <description>Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.</description>
    <arm_group_label>Gastroenteropancreatic neuroendocrine neoplasms</arm_group_label>
    <arm_group_label>Pancreatic ductal adenocarcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Collect specimens confirmed to be NEN or PDAC by surgery or biopsy histopathology for&#xD;
        single-cell sequencing analysis and the construction of primary cells, organoids and animal&#xD;
        models.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between the ages of 18 and 80, with any gender;&#xD;
&#xD;
          2. Physical fitness score ECOG 0～1 points;&#xD;
&#xD;
          3. The diagnosis is considered as gastrointestinal pancreatic neuroendocrine tumor or&#xD;
             pancreatic ductal adenocarcinoma;&#xD;
&#xD;
          4. There is no obvious contraindication to surgery or biopsy;&#xD;
&#xD;
          5. Uncompensated liver cirrhosis, acute and chronic hepatitis and other diseases;&#xD;
&#xD;
          6. No history of other biliary tract related diseases;&#xD;
&#xD;
          7. Volunteer to participate and sign the informed consent form. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with non-gastrointestinal pancreatic neuroendocrine tumors or pancreatic&#xD;
             ductal adenocarcinoma confirmed pathologically;&#xD;
&#xD;
          2. Suffer from other digestive system diseases, such as irritable bowel syndrome,&#xD;
             inflammatory bowel disease;&#xD;
&#xD;
          3. Those who have incomplete follow-up data or refuse to accept follow-up;&#xD;
&#xD;
          4. Patients with other malignant tumors or hematological diseases; -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianjun Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xianjun Yu, MD, PhD</last_name>
    <phone>+86-13801669875</phone>
    <email>yuxianjun@fudanpci.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianjun Yu, M.D., Ph.D.</last_name>
      <phone>+86-21-6417-5590</phone>
      <email>yuxianjun@fudanpci.org</email>
    </contact>
    <investigator>
      <last_name>Xianjun Yu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after &quot;carcinoid&quot;: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377. Review.</citation>
    <PMID>18565894</PMID>
  </reference>
  <reference>
    <citation>Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005 May;128(6):1717-51. Review.</citation>
    <PMID>15887161</PMID>
  </reference>
  <reference>
    <citation>Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.</citation>
    <PMID>28448665</PMID>
  </reference>
  <reference>
    <citation>Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015 Feb 15;121(4):589-97. doi: 10.1002/cncr.29099. Epub 2014 Oct 13.</citation>
    <PMID>25312765</PMID>
  </reference>
  <reference>
    <citation>Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008 Jan;9(1):61-72. doi: 10.1016/S1470-2045(07)70410-2. Review.</citation>
    <PMID>18177818</PMID>
  </reference>
  <reference>
    <citation>Saxena A, Chua TC, Sarkar A, Chu F, Liauw W, Zhao J, Morris DL. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery. 2011 Feb;149(2):209-20. doi: 10.1016/j.surg.2010.06.008. Epub 2010 Aug 2.</citation>
    <PMID>20674950</PMID>
  </reference>
  <reference>
    <citation>Pape UF, Berndt U, Müller-Nordhorn J, Böhmig M, Roll S, Koch M, Willich SN, Wiedenmann B. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008 Dec;15(4):1083-97. doi: 10.1677/ERC-08-0017. Epub 2008 Jul 4.</citation>
    <PMID>18603570</PMID>
  </reference>
  <reference>
    <citation>Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157-76. doi: 10.1159/000335597. Epub 2012 Feb 15.</citation>
    <PMID>22262022</PMID>
  </reference>
  <reference>
    <citation>Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R; Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014 Jan;15(1):e8-21. doi: 10.1016/S1470-2045(13)70362-0. Review.</citation>
    <PMID>24384494</PMID>
  </reference>
  <reference>
    <citation>Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012 Mar 20;21(3):309-22. doi: 10.1016/j.ccr.2012.02.022. Review.</citation>
    <PMID>22439926</PMID>
  </reference>
  <reference>
    <citation>Baryawno N, Przybylski D, Kowalczyk MS, Kfoury Y, Severe N, Gustafsson K, Kokkaliaris KD, Mercier F, Tabaka M, Hofree M, Dionne D, Papazian A, Lee D, Ashenberg O, Subramanian A, Vaishnav ED, Rozenblatt-Rosen O, Regev A, Scadden DT. A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia. Cell. 2019 Jun 13;177(7):1915-1932.e16. doi: 10.1016/j.cell.2019.04.040. Epub 2019 May 23.</citation>
    <PMID>31130381</PMID>
  </reference>
  <reference>
    <citation>Ren X, Kang B, Zhang Z. Understanding tumor ecosystems by single-cell sequencing: promises and limitations. Genome Biol. 2018 Dec 3;19(1):211. doi: 10.1186/s13059-018-1593-z. Review.</citation>
    <PMID>30509292</PMID>
  </reference>
  <reference>
    <citation>Heath JR, Ribas A, Mischel PS. Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov. 2016 Mar;15(3):204-16. doi: 10.1038/nrd.2015.16. Epub 2015 Dec 16. Review.</citation>
    <PMID>26669673</PMID>
  </reference>
  <reference>
    <citation>Lytle NK, Ferguson LP, Rajbhandari N, Gilroy K, Fox RG, Deshpande A, Schürch CM, Hamilton M, Robertson N, Lin W, Noel P, Wartenberg M, Zlobec I, Eichmann M, Galván JA, Karamitopoulou E, Gilderman T, Esparza LA, Shima Y, Spahn P, French R, Lewis NE, Fisch KM, Sasik R, Rosenthal SB, Kritzik M, Von Hoff D, Han H, Ideker T, Deshpande AJ, Lowy AM, Adams PD, Reya T. A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. Cell. 2019 Apr 18;177(3):572-586.e22. doi: 10.1016/j.cell.2019.03.010. Epub 2019 Apr 4.</citation>
    <PMID>30955884</PMID>
  </reference>
  <reference>
    <citation>Kumar MP, Du J, Lagoudas G, Jiao Y, Sawyer A, Drummond DC, Lauffenburger DA, Raue A. Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics. Cell Rep. 2018 Nov 6;25(6):1458-1468.e4. doi: 10.1016/j.celrep.2018.10.047.</citation>
    <PMID>30404002</PMID>
  </reference>
  <reference>
    <citation>Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009 May 14;459(7244):262-5. doi: 10.1038/nature07935. Epub 2009 Mar 29.</citation>
    <PMID>19329995</PMID>
  </reference>
  <reference>
    <citation>Jung P, Sato T, Merlos-Suárez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo M, Blasco MA, Sancho E, Clevers H, Batlle E. Isolation and in vitro expansion of human colonic stem cells. Nat Med. 2011 Sep 4;17(10):1225-7. doi: 10.1038/nm.2470.</citation>
    <PMID>21892181</PMID>
  </reference>
  <reference>
    <citation>Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, Vries RGJ, Cuppen E, Chen Y, Sawyers CL, Clevers HC. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 2014 Sep 25;159(1):163-175. doi: 10.1016/j.cell.2014.08.017. Epub 2014 Sep 4.</citation>
    <PMID>25201529</PMID>
  </reference>
  <reference>
    <citation>Chua CW, Shibata M, Lei M, Toivanen R, Barlow LJ, Bergren SK, Badani KK, McKiernan JM, Benson MC, Hibshoosh H, Shen MM. Single luminal epithelial progenitors can generate prostate organoids in culture. Nat Cell Biol. 2014 Oct;16(10):951-61, 1-4. doi: 10.1038/ncb3047. Epub 2014 Sep 21.</citation>
    <PMID>25241035</PMID>
  </reference>
  <reference>
    <citation>Kessler M, Hoffmann K, Brinkmann V, Thieck O, Jackisch S, Toelle B, Berger H, Mollenkopf HJ, Mangler M, Sehouli J, Fotopoulou C, Meyer TF. The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids. Nat Commun. 2015 Dec 8;6:8989. doi: 10.1038/ncomms9989.</citation>
    <PMID>26643275</PMID>
  </reference>
  <reference>
    <citation>Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi: 10.1038/ncomms3612.</citation>
    <PMID>24113773</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>September 19, 2021</last_update_submitted>
  <last_update_submitted_qc>September 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xian-Jun Yu</investigator_full_name>
    <investigator_title>President of Shanghai Pancreatic Cancer Institute</investigator_title>
  </responsible_party>
  <keyword>Neuroendocrine Neoplasm</keyword>
  <keyword>Single Cell Sequencing Technology</keyword>
  <keyword>Primary Cell Culture</keyword>
  <keyword>Organoid</keyword>
  <keyword>Patient-derived Tumor Xenograft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

